Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Infantile-onset Pompe disease (IOPD) is a rare inherited neuromuscular disorder caused by acid alpha-glucosidase deficiency, leading to glycogen accumulation in muscles. As per Weijing Kong et al. (2024), the global birth prevalence of IOPD was 1 per 100,000 live births. According to the infantile-onset Pompe disease (IOPD) epidemiology forecast by Expert Market Research, epidemiological trends remain important for understanding the disease burden, patient population, and evolving patterns of diagnosis across the eight major markets.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Infantile-Onset Pompe Disease (IOPD) – Number of Cases by Year

Read more about this report - Request a Free Sample

Infantile-Onset Pompe Disease (IOPD) Epidemiology Forecast Report Coverage

Expert Market Research's “Infantile-Onset Pompe Disease (IOPD) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of infantile-onset Pompe disease (IOPD). It projects the future incidence and prevalence rates of infantile-onset Pompe disease (IOPD) cases across various populations. The study covers age, gender, and type as major determinants of the infantile-onset Pompe disease (IOPD) population. The report highlights patterns in the prevalence of infantile-onset Pompe disease (IOPD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of infantile-onset pompe disease (IOPD) in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Infantile-Onset Pompe Disease (IOPD) Understanding: Disease Overview

Infantile-onset Pompe disease (IOPD) is a rare, autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GAA gene, resulting in deficient acid alpha-glucosidase (GAA) activity and progressive glycogen accumulation, particularly in cardiac and skeletal muscle. Classic IOPD typically presents within the first year of life with generalized hypotonia, muscle weakness, feeding difficulties, respiratory impairment, and hypertrophic cardiomyopathy. Pompe disease is broadly classified into infantile-onset and late-onset forms, with IOPD representing the more rapidly progressive phenotype. GAA enzyme deficiency is the underlying biochemical abnormality.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Newborns with biallelic pathogenic GAA variants, particularly infants with severe GAA deficiency and CRIM-negative status.

Key Diagnostic Method

Newborn screening using dried blood spots for GAA enzyme activity, followed by confirmatory enzyme and molecular genetic testing.

Major Risk Factor

Pathogenic variants in the GAA gene inherited in an autosomal recessive pattern.

Major gap in the market

Delayed or incomplete diagnosis and uneven access to newborn screening, particularly where systematic screening and confirmatory testing are less established.

Infantile-Onset Pompe Disease (IOPD) Epidemiology Perspective

The infantile-onset Pompe disease (IOPD) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the infantile-onset Pompe disease (IOPD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for infantile-onset Pompe disease (IOPD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Weijing Kong et al. (2024), the global birth prevalence of infantile-onset Pompe disease was 1.0 case per 100,000 live births (95% CI: 0.5–1.5). According to Sanofi, IOPD prevalence is approximately 1 in 138,000 people.

Gender-Specific Cases of the Disease

Epidemiological assessment of IOPD encompasses both male and female populations, with disease occurrence primarily evaluated through birth-screening and diagnostic programs. The available epidemiological findings emphasize geographic and population-level differences rather than sex-specific variation.

Age-Specific Cases of the Disease

IOPD is characterized by disease presentation during infancy. Classic IOPD can present during the first days of life, while non-classic IOPD generally presents during the first year, establishing infancy as the principal age group for disease identification.

Ethnicity-Wise Cases of the Disease

According to Roberto Giugliani et al. (2025), epidemiological estimates vary according to geographic and ethnic populations. Studies have reported higher prevalence among populations of African descent, while pseudodeficiency alleles occur more frequently in some Asian populations.

Mortality and Survival Analysis of the Disease

IOPD has a substantial early-life disease burden, particularly in classic presentations. Untreated classic IOPD may result in death during the first year because of hypertrophic cardiomyopathy, while non-classic disease generally follows a slower progression.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Classic IOPD

Classic IOPD represents the severe infantile presentation, with onset during the first days of life and rapid disease progression characterized by cardiomyopathy, muscle weakness, and respiratory involvement.

Non-classic IOPD

Non-classic IOPD generally presents during the first year of life and follows a slower progression than classic IOPD, although progressive muscle weakness and respiratory complications contribute to disease burden.

Infantile-Onset Pompe Disease (IOPD) – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Infantile-Onset Pompe Disease (IOPD) Epidemiology

The infantile-onset Pompe disease (IOPD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to the Muscular Dystrophy Association, Pompe disease occurs in approximately 1 in 22,000 live births in the United States. The United States therefore represents an important population for epidemiological assessment through newborn screening, diagnostic testing, and identification of infantile presentations.

Germany

Germany contributes to the European epidemiological landscape of Pompe disease, where prevalence estimates vary across populations and diagnostic approaches. European studies constitute a substantial component of the available epidemiological evidence, supporting continued assessment of birth prevalence and early diagnosis of IOPD.

France

According to Roberto Giugliani et al. (2025), the French National Pompe Registry included 246 individuals and demonstrated increasing diagnosis of late-onset Pompe disease over successive periods. The French epidemiological landscape also reflects the importance of registry-based identification and longitudinal disease surveillance.

Italy

Italy forms part of the European newborn-screening landscape for Pompe disease. Epidemiological assessment in the country is associated with newborn screening and identification of affected infants, supporting earlier recognition of IOPD within the pediatric population.

Spain

Spain represents part of the European epidemiological context for Pompe disease, where population-based diagnosis and newborn screening contribute to identifying affected infants. The broader European evidence demonstrates geographic variation in Pompe disease birth prevalence.

United Kingdom

According to Jordi Díaz-Manera et al. (2025), Pompe disease prevalence in the United Kingdom is approximately 1 in 40,000, while the worldwide incidence of IOPD is approximately 1 in 138,000. The source estimates 35–40 children living with IOPD in the United Kingdom.

Japan

As per Roberto Giugliani et al. (2025), newborn-screening studies estimated IOPD birth prevalence at approximately 1 in 297,387 in Japan. This finding illustrates geographic variation in IOPD prevalence and highlights the contribution of newborn screening to identifying affected infants.

India

India represents a large pediatric population in which recognition of rare inherited disorders such as IOPD depends on early clinical identification, biochemical assessment, and genetic confirmation. Epidemiological assessment is particularly relevant to improving recognition of affected infants and understanding population-level disease burden.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

A major epidemiological gap in IOPD is the inconsistent availability and implementation of newborn screening across countries, which can delay diagnosis and treatment during a period when disease progression may be rapid. Expanding standardized newborn screening, particularly in India, could improve early case identification and facilitate timely confirmatory testing and treatment. Another opportunity involves strengthening molecular testing and CRIM-status assessment following abnormal screening results. Across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India, greater harmonization of diagnostic pathways and longitudinal epidemiological registries could improve estimates of disease burden and treatment needs.

Infantile-Onset Pompe Disease (IOPD): Treatment Overview

Infantile-onset Pompe disease treatment requires early initiation of disease-specific therapy to limit irreversible muscle and cardiac damage. Enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase is the principal targeted treatment and should generally begin promptly after diagnosis. Before ERT, cross-reactive immunologic material (CRIM) status is assessed because CRIM-negative infants are at increased risk of developing high-titer antibodies against the replacement enzyme. Immunomodulatory therapy may therefore be administered alongside ERT to promote immune tolerance. Multidisciplinary supportive care, including respiratory, nutritional, cardiac, physical, and developmental management, is also important.

Key Questions Answered

  • What is the current and projected burden of infantile-onset Pompe disease (IOPD) across the 8 major markets?
  • Which countries across the 8 major markets account for the highest infantile-onset Pompe disease (IOPD) patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of infantile-onset Pompe disease (IOPD) across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of infantile-onset Pompe disease (IOPD) across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of infantile-onset Pompe disease (IOPD) across the 8 major markets?
  • How do major comorbidities and risk factors influence infantile-onset Pompe disease (IOPD) epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of infantile-onset Pompe disease (IOPD) across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the infantile-onset Pompe disease (IOPD) landscape across the 8 major markets?
  • Which therapeutic areas linked to infantile-onset Pompe disease (IOPD) are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the infantile-onset Pompe disease (IOPD) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on infantile-onset Pompe disease (IOPD) epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for infantile-onset Pompe disease (IOPD) across the 8 major markets?

Scope of the Infantile-Onset Pompe Disease (IOPD) Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of infantile-onset Pompe disease (IOPD) based on several factors.
  • Infantile-Onset Pompe Disease (IOPD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The infantile-onset Pompe disease (IOPD) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Hypertrophic Cardiomyopathy Pipeline Analysis

Rare Diseases Treatment Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us